Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-0431 add-on to metformin in type 2 diabetes
2004-000312-93Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Jun 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Sitagliptin add-on to metformin with Placebo add-on to metformin (2 arms). Primary endpoints: HbA1c and Safety and tolerability. Started Jun 2004; status: completed.
02
Drugs
sitagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2004-000312-93.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-000312-93.